INDIANAPOLIS, Aug. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. presented data at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., announcing the discovery of novel multi-targeted kinase inhibitors that demonstrate significant anticancer activity in preclinical studies.
A novel and proprietary molecular scaffold has been developed using computational modeling allowing for the design of pan-PI3 kinase inhibitors as well as isoform-selective small molecule PI3 kinase inhibitors. The scaffold also allows for the design of compounds that can be administered orally or intravenously. Of 50 compounds identified, SF2523 and SF2506 have been chosen for additional evaluation based on their ability to inhibit multiple kinases, including PI3K, mTOR, DNA-PK and PIM-1. SF2523 and SF2506 also have dramatically increased potency relative to the well-known PI3 kinase inhibitor LY294002. Both inhibitors demonstrated the ability to significantly induce apoptosis in a renal cell carcinoma cell line (786-0).
Evaluation of SF2523 in a 232 kinase panel screen showed that the compound selectively and potently inhibits key cancer kinase targets, including mTOR, DNA-PK, PIM-1 and PI3K. SF2523 demonstrated potent anticancer proliferation activity across a broad range of 18 cancer cell lines representing solid tumors (lung, pancreatic, prostate, colon, breast, brain, ovarian, renal and melanoma) and hematological malignancies (AML, CML and multiple myeloma). Notably, SF2523 inhibited proliferation in multiple cell lines with KRAS mutations, including HCT116-colon, A549 lung, BXPC3 pancreatic and RPMI8226 myeloma cell lines. Colorectal cancer patients with KRAS mutations have been identified as less likely to respond to EGFR inhibitors (ASCO 08). New compounds with activity against KRAS mutations are being actively pursued to address the unmet medical need.
In vivo testing of SF2523 in renal cell carcinoma (RCC) mouse xenograft models demonstrated 81 percent tumor growth inhibition. SF2506 testing resulted in 93 percent tumor growth reduction in the same model.
"Semafore's proprietary kinase scaffold and our new multi-targeted kinase inhibitors add significant value to our pipeline," said Dr. Dennis McKeever, Semafore's Chief Executive Officer. "In addition to inhibiting all Class I isoforms of PI3K, our compounds SF2506 and SF2523 block additional key kinases which is in keeping with the multi-targeting philosophy behind other recent successful molecularly targeted agents."
Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus -- cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The company has successfully discovered and is developing a portfolio of drug candidates addressing these targets.
There is a strong and significant biological rationale for developing PI3 kinase inhibitors to treat cancer. Phosphoinositide 3-kinase (PI3K) is the gate keeper of one of the major pathways of intracellular signal transduction that regulates cell growth, proliferation, angiogenesis, migration, differentiation, and survival. Dysregulation of the PI3K signaling pathway is believed to play an integral role in the genesis of many cancers including both solid tumors and hematologic malignancies. Cancer research and pharmaceutical drug development efforts have been aimed at discovering and developing therapeutics that inhibit PI3K with the hope of controlling cancer cell division, angiogenesis (the formation of new blood vessels for cancer growth), proliferation and metastasis. Semafore's innovative PI3K inhibitor, SF1126, promises such hope for cancer patients.
SF1126, is a proprietary small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTOR, DNA-PK, PLK-1, CK2, ATM and PIM-1 kinases all known to be involved in the cascade of chemical signals that control cell division. Importantly, SF1126 is designed as a dual inhibitor of both angiogenesis and cell proliferation. SF1126 is engineered to target and bind to specific integrins (alpha gamma beta 3) that are expressed on the surface of new tumor vasculature and within the tumor endothelial compartment. In tumor xenograph models Semafore demonstrated enhanced drug uptake of SF1126 which was directly attributable to the alpha gamma beta 3 targeted moiety. SF1126 is water soluble, has favorable pharmacokinetics and is well tolerated.
SF1126 is currently in Phase I clinical trials in both solid tumors and multiple myeloma.
For more information see the company's Web site at http://www.SemaforePharma.com.
|SOURCE Semafore Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved